Kindeva Drug Delivery, a global company specialising in optimising drug delivery, announced the expansion of its analytical services capabilities.
For more than half a century, Kindeva has developed significant knowledge, experience, and expertise working on inhaled, injectable, and transdermal drug delivery development programs and cGMP commercial supply.
Additionally, Kindeva has built deep expertise and capability in cGMP analytical services supporting its product development and supply partners.
In addition to increasing Kindeva’s global analytical footprint, Kindeva’s recently opened 32,000-square-foot state-of-the-art laboratories in Woodbury, Minnesota, will serve as the central hub for its expanded suite of stand-alone analytical services.
Kindeva’s Global Chief Commercial Officer Dave Stevens added: “Offering considerable analytical testing capabilities on a stand-alone basis to the wider pharmaceutical and device industry is an important step for Kindeva’s growing role as a contract analytical, development and manufacturing organisation. 2024 is an exciting year for bringing many areas of needed industry solutions to fruition with the opening of a brand new sterile injectable facility in Bridgeton, Missouri — capable of manufacturing more than 100M vials, cartridges and syringes — as well as the operationalisation of our first 152a green propellant-capable GMP capacity in Loughborough, U.K.”
Kindeva will offer extractables and leachables, elemental impurities, medical device and container closure integrity testing.